Palogic Value Management L.P. Acquires Shares of 320,000 Health Catalyst, Inc. (NASDAQ:HCAT)

Palogic Value Management L.P. acquired a new position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 320,000 shares of the company's stock, valued at approximately $2,262,000. Palogic Value Management L.P. owned about 0.46% of Health Catalyst as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. First Light Asset Management LLC boosted its position in Health Catalyst by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock valued at $37,055,000 after acquiring an additional 944,631 shares during the last quarter. Impax Asset Management Group plc boosted its position in Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after acquiring an additional 195,525 shares during the last quarter. Daventry Group LP boosted its position in Health Catalyst by 3.8% during the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock valued at $17,742,000 after acquiring an additional 91,878 shares during the last quarter. Alyeska Investment Group L.P. boosted its position in Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after acquiring an additional 861,150 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its position in Health Catalyst by 42.7% during the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock valued at $13,369,000 after acquiring an additional 565,445 shares during the last quarter. Institutional investors own 85.00% of the company's stock.

Health Catalyst Stock Up 1.1%

Shares of HCAT stock traded up $0.04 on Friday, reaching $3.78. 565,285 shares of the company were exchanged, compared to its average volume of 600,703. The company has a market cap of $263.09 million, a price-to-earnings ratio of -2.80 and a beta of 1.56. The company has a 50-day moving average of $4.00 and a 200-day moving average of $5.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a one year low of $3.49 and a one year high of $9.24.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Stifel Nicolaus upped their price target on shares of Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research report on Thursday, May 8th. Piper Sandler cut their price target on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. Evercore ISI cut shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Canaccord Genuity Group cut their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Stephens cut their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Health Catalyst has an average rating of "Moderate Buy" and an average target price of $8.00.

Insider Buying and Selling

In related news, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now owns 216,250 shares in the company, valued at $977,450. This represents a 7.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,147 shares of company stock worth $182,284 in the last quarter. Insiders own 2.50% of the company's stock.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.